Regulatory News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), ("Onxeo" or the "Company"), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced its financial agenda for 2018.
Event | Date* | |
Full-year 2017 results | Thursday, March 29, 2018 | |
Q1 2018 financial information | Friday, May 4, 2018 | |
Shareholders' general meeting | Wednesday, May 16, 2018 | |
Half-year 2018 results | Friday, July 27, 2018 | |
Q3 2018 financial information | Thursday, October 25, 2018 |
This preliminary agenda may be modified. Press releases are published after financial markets close.
About Onxeo
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a French biotechnology company developing innovative oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after mechanisms of action in cancer treatment today. The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
Onxeo's R&D pipeline includes belinostat, an HDAC inhibitor (epigenetics) currently being developed in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors. Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo's partner, Spectrum Pharmaceuticals, under the name Beleodaq (belinostat IV form).
Onxeo is also developing AsiDNA, a first-in-class DNA break repair inhibitor based on a unique decoy mechanism. AsiDNA has already successfully completed a Phase I trial in metastatic melanoma via local administration, and is currently being developed for systemic (IV) administration in solid tumors.
AsiDNA is the first compound generated from platON, the Company's proprietary chemistry platform of decoy oligonucleotides based on three components, a sequence of double strand oligonucleotides, a linker and a cellular uptake facilitator. PlatON will continue to generate new compounds that will broaden Onxeo's pipeline.
For further information, please visit www.onxeo.com
Forward looking statements
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 5.5.1.4 "Risk Factors" ("Facteurs de Risque") of the 2016 reference document filed with the Autorité des marchés financiers on April 24, 2017 under number D.17-0423, which is available on the Autorité des marchés financiers website (www.amf-france.org) or on the Company's website (www.onxeo.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180123006178/en/
Contacts:
Onxeo
Valerie Leroy,
Investor Relations
investors@onxeo.com
+33 1 45 58 76 00
or
Media Relations
Caroline Carmagnol alize-onxeo@alizerp.com
+33 6 64 18 99 59
or
Investor Relations Strategic Communication
Dušan Orešanský Emmanuel Huynh
NewCap
onxeo@newcap.eu
+33 1 44 71 94 92
or
Investor Relations US
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
+1 212 915 2578